4.1 Article

A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis

Journal

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/21678421.2017.1404108

Keywords

ALS; tolerability; benefit; motor neuron disease; clinical trial

Funding

  1. ALS Association [1489]
  2. William Gray Smith Fund at Johns Hopkins

Ask authors/readers for more resources

Objective: Evaluate the safety and tolerability of resistance and endurance exercise in ALS participants as measured by their ability to complete this six-month study. Methods: Participants were randomized to Resistance, Endurance, or Stretching/Range of Motion (SROM the exercise regimen prescribed for most ALS patients) exercises. All exercises were performed at home with an individualized regimen designed by a physical therapist trained in ALS management. Primary outcome measures were tolerability of the exercises at 24 weeks defined by 50% of participants completing at least 50% of the prescribed exercise regimen. Secondary outcome measures included the ALSFRS-R, pulmonary FVC, and other measures of ALS function. Results: At 12 and 24 weeks, all three exercise regimens were tolerated according to our pre-specified criteria. Compliance to the prescribed exercise regimen was the highest in the resistance and SROM arms of the study. All three forms of exercise were considered safe as there were no differences in the rates of disease progression among groups. There were no differences in the secondary outcome measures and feasibility for evaluating these measures was successful. In a post-hoc analysis, there was a trend towards fewer falls in the Resistance and Endurance groups. Conclusions: This study demonstrates that SROM, resistance, and endurance exercise are all safe to be performed with the specified regimen without any worsening of outcomes as related to ALS function. All three forms of exercise were tolerated with resistance and SROM exercises showing the highest compliance over the 24 week-period.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles

Carolyn Young, Susana Pinto, Julian Grosskreutz, Orla Hardiman, Lora L. Clawson, Merit E. Cudkowicz, Jinsy A. Andrews

Summary: The roundtable meeting discussed respiratory support in ALS patients, highlighting the potential of orally administered medication in delaying the introduction of NIV or enhancing its benefits. Furthermore, attention was given to the impact of the COVID-19 pandemic on the usual assessment and management practices for respiratory difficulties in ALS patients.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2022)

Article Clinical Neurology

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development

Sabrina Paganoni, James D. Berry, Melanie Quintana, Eric Macklin, Benjamin R. Saville, Michelle A. Detry, Marianne Chase, Alexander Sherman, Hong Yu, Kristin Drake, Jinsy Andrews, Jeremy Shefner, Lori B. Chibnik, Matteo Vestrucci, Merit E. Cudkowicz

Summary: The current therapeutic development in ALS faces limitations in terms of cost, time, and flexibility due to individual randomized clinical trials. Adaptive platform trials provide a novel approach to investigate multiple interventions for a single disease continuously. The Healey ALS Platform Trial is a recently launched trial that aims to identify novel treatments, biomarkers, and trial endpoints rapidly by testing multiple investigational products concurrently in ALS patients.

ANNALS OF NEUROLOGY (2022)

Article Clinical Neurology

Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid

Tiziana Petrozziello, Ana C. Amaral, Simon Dujardin, Sali M. K. Farhan, James Chan, Bianca A. Trombetta, Pia Kivisakk, Alexandra N. Mills, Evan A. Bordt, Spencer E. Kim, Patrick M. Dooley, Caitlin Commins, Theresa R. Connors, Derek H. Oakley, Anubrata Ghosal, Teresa Gomez-Isla, Bradley T. Hyman, Steven E. Arnold, Tara Spires-Jones, Merit E. Cudkowicz, James D. Berry, Ghazaleh Sadri-Vakili

Summary: This study found alterations in tau phosphorylation in post-mortem motor cortex of ALS patients, especially increased total tau and pTau-S396 in C9ORF72-ALS. Levels of total tau in cerebrospinal fluid were associated with disease progression speed, while the pTau-T181:tau ratio correlated with disease progression speed.

BRAIN PATHOLOGY (2022)

Article Neurosciences

Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis

Tiziana Petrozziello, Evan A. Bordt, Alexandra N. Mills, Spencer E. Kim, Ellen Sapp, Benjamin A. Devlin, Abigail A. Obeng-Marnu, Sali M. K. Farhan, Ana C. Amaral, Simon Dujardin, Patrick M. Dooley, Christopher Henstridge, Derek H. Oakley, Andreas Neueder, Bradley T. Hyman, Tara L. Spires-Jones, Staci D. Bilbo, Khashayar Vakili, Merit E. Cudkowicz, James D. Berry, Marian DiFiglia, M. Catarina Silva, Stephen J. Haggarty, Ghazaleh Sadri-Vakili

Summary: Research suggests that increased levels of hyperphosphorylated tau may lead to mitochondrial fragmentation and oxidative stress in amyotrophic lateral sclerosis (ALS); reducing tau levels could potentially alleviate mitochondrial dysfunction in ALS.

MOLECULAR NEUROBIOLOGY (2022)

Article Clinical Neurology

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses

Robert G. Miller, Rongzhen Zhang, Paige M. Bracci, Ari Azhir, Richard Barohn, Richard Bedlack, Michael Benatar, James D. Berry, Merit Cudkowicz, Edward J. Kasarskis, Hiroshi Mitsumoto, Georgios Manousakis, David Walk, Bjorn Oskarsson, Jeremy Shefner, Michael S. McGrath

Summary: ALS is a complex disease that may be influenced by inflammation. This study found that NP001, which regulates macrophage activation, could slow down disease progression in ALS patients with higher levels of the inflammatory marker CRP. Although the phase 2B trial did not meet its primary endpoints, post hoc analysis identified a subset of patients aged 40-65 years who showed significantly slower decline in ALSFRS-R scores and vital capacity loss when treated with NP001.

MUSCLE & NERVE (2022)

Article Clinical Neurology

A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

Merit E. Cudkowicz, Stacy R. Lindborg, Namita A. Goyal, Robert G. Miller, Matthew J. Burford, James D. Berry, Katharine A. Nicholson, Tahseen Mozaffar, Jonathan S. Katz, Liberty J. Jenkins, Robert H. Baloh, Richard A. Lewis, Nathan P. Staff, Margaret A. Owegi, Donald A. Berry, Yael Gothelf, Yossef S. Levy, Revital Aricha, Ralph Z. Kern, Anthony J. Windebank, Robert H. Brown

Summary: This study evaluated the efficacy of mesenchymal stem cells induced to secrete neurotrophic factors in slowing the progression of ALS. The results suggest that this therapy may have a positive effect on patients with less severe disease, but did not reach statistical significance on the primary endpoint.

MUSCLE & NERVE (2022)

Article Neurosciences

Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines

Emily G. Baxi, Terri Thompson, Jonathan Li, Julia A. Kaye, Ryan G. Lim, Jie Wu, Divya Ramamoorthy, Leandro Lima, Vineet Vaibhav, Andrea Matlock, Aaron Frank, Alyssa N. Coyne, Barry Landin, Loren Ornelas, Elizabeth Mosmiller, Sara Thrower, S. Michelle Farr, Lindsey Panther, Emilda Gomez, Erick Galvez, Daniel Perez, Imara Meepe, Susan Lei, Berhan Mandefro, Hannah Trost, Louis Pinedo, Maria G. Banuelos, Chunyan Liu, Ruby Moran, Veronica Garcia, Michael Workman, Richie Ho, Stacia Wyman, Jennifer Roggenbuck, Matthew B. Harms, Jennifer Stocksdale, Ricardo Miramontes, Keona Wang, Vidya Venkatraman, Ronald Holewenski, Niveda Sundararaman, Rakhi Pandey, Danica-Mae Manalo, Aneesh Donde, Nhan Huynh, Miriam Adam, Brook T. Wassie, Edward Vertudes, Naufa Amirani, Krishna Raja, Reuben Thomas, Lindsey Hayes, Alex Lenail, Aianna Cerezo, Sarah Luppino, Alanna Farrar, Lindsay Pothier, Carolyn Prina, Todd Morgan, Arish Jamil, Sarah Heintzman, Jennifer Jockel-Balsarotti, Elizabeth Karanja, Jesse Markway, Molly McCallum, Ben Joslin, Deniz Alibazoglu, Stephen Kolb, Senda Ajroud-Driss, Robert Baloh, Daragh Heitzman, Tim Miller, Jonathan D. Glass, Natasha Leanna Patel-Murray, Hong Yu, Ervin Sinani, Prasha Vigneswaran, Alexander V. Sherman, Omar Ahmad, Promit Roy, Jay C. Beavers, Steven Zeiler, John W. Krakauer, Carla Agurto, Guillermo Cecchi, Mary Bellard, Yogindra Raghav, Karen Sachs, Tobias Ehrenberger, Elizabeth Bruce, Merit E. Cudkowicz, Nicholas Maragakis, Raquel Norel, Jennifer E. Van Eyk, Steven Finkbeiner, James Berry, Dhruv Sareen, Leslie M. Thompson, Ernest Fraenkel, Clive N. Svendsen, Jeffrey D. Rothstein

Summary: Answer ALS is a resource that includes patient-derived iPS cell lines, multi-omic data from iPS neurons, and clinical and smartphone data from over 1,000 ALS patients. This data can be used to identify distinct disease subgroups in ALS.

NATURE NEUROSCIENCE (2022)

Article Clinical Neurology

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis The BeatMG Study

Richard J. Nowak, Christopher S. Coffey, Jonathan M. Goldstein, Mazen M. Dimachkie, Michael Benatar, John T. Kissel, Gil Wolfe, Ted M. Burns, Miriam L. Freimer, Sharon Nations, Volkan Granit, A. Gordon Smith, David P. Richman, Emma Ciafaloni, Muhammad T. Al-Lozi, Laura Ann Sams, Dianna Quan, Eroboghene Ubogu, Brenda Pearson, Aditi Sharma, Jon W. Yankey, Liz Uribe, Michael Shy, Anthony A. Amato, Robin Conwit, Kevin C. O'Connor, David A. Hafler, Merit E. Cudkowicz, Richard J. Barohn

Summary: This study suggests that rituximab is safe but unlikely to significantly reduce steroid use in patients with mild to moderate symptoms of AChR-Ab+ gMG.

NEUROLOGY (2022)

Review Clinical Neurology

ALSUntangled #63: ketogenic diets

Richard Bedlack, Paul E. Barkhaus, Benjamin Barnes, Morgan Beauchamp, Tulio Bertorini, Mark B. Bromberg, Gregory T. Carter, Vinay Chaudry, Merit Cudkowicz, Ce Jackson, Gleb Levitsky, Isaac Lund, Christopher McDermott, Steven Novella, Natasha Olby, Lyle Ostrow, Gary L. Pattee, Terry Heiman-Patterson, Dylan Ratner, Kristiana Salmon, Susan Steves, Mark Terrelonge, Paul Wicks, Anne-Marie Wills

Summary: ALSUntangled reviews the effectiveness of ketogenic diets for ALS patients and finds that they may work by enhancing cellular energy balance and reducing excitotoxicity, neuroinflammation, and oxidative stress. However, there is currently insufficient data to recommend ketogenic diets for ALS patients, especially considering the potential side effects.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS

Jonathan S. Katz, Jeffrey D. Rothstein, Merit E. Cudkowicz, Angela Genge, Bjorn Oskarsson, Avis B. Hains, Chen Chen, Joshua Galanter, Braydon L. Burgess, William Cho, Geoffrey A. Kerchner, Felix L. Yeh, Arundhati Sengupta Ghosh, Sravanthi Cheeti, Logan Brooks, Lee Honigberg, Jessica A. Couch, Michael E. Rothenberg, Flavia Brunstein, Khema R. Sharma, Leonard van den Berg, James D. Berry, Jonathan D. Glass

Summary: This study investigated the safety, tolerability, and pharmacokinetics of GDC-0134, a potential therapeutic drug for ALS. Results showed good tolerability of GDC-0134 at appropriate doses, but no tolerated dose was identified. The study also found changes in plasma neurofilament light chain levels in GDC-0134-treated patients and mice.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Article Clinical Neurology

An expanded access protocol of RT001 in amyotrophic lateral sclerosis---Initial experience with a lipid peroxidation inhibitor

Megan Yerton, Allison Winter, Anthony Kostov, Cassandra Lieberman, Dario Gelevski, Harli Weber, Michael Doyle, Geli Kane, Neil Parikh, Katherine M. Burke, Margot Rohrer, Taylor Stirrat, Margaret Bruno, Alison Hochman, Sarah Luppino, Jennifer Scalia, Debra Skoniecki, Derek D'Agostino, Ervin Sinani, Hong Yu, Alexander Sherman, Suma Babu, James D. Berry, Mark G. Midei, Peter G. Milner, Merit E. Cudkowicz, Sabrina Paganoni

Summary: This study reports on the use of 11,11 Di-deuterated linoleic ethyl ester (RT001) in patients with amyotrophic lateral sclerosis (ALS) under expanded access. The results show that RT001 can prevent lipid peroxidation in cellular and mitochondrial membranes and has a therapeutic effect in some patients. The observed adverse events were mostly gastrointestinal and considered to have a low correlation with the use of RT001.

MUSCLE & NERVE (2022)

Editorial Material Clinical Neurology

Preventing Amyotrophic Lateral Sclerosis Before It Starts: When to Intervene?

Merit Cudkowicz

NEUROTHERAPEUTICS (2022)

Article Geriatrics & Gerontology

Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery Platform

Frank W. Pun, Bonnie Hei Man Liu, Xi Long, Hoi Wing Leung, Geoffrey Ho Duen Leung, Quinlan T. Mewborne, Junli Gao, Anastasia Shneyderman, Ivan V. Ozerov, Ju Wang, Feng Ren, Alexander Aliper, Evelyne Bischof, Evgeny Izumchenko, Xiaoming Guan, Ke Zhang, Bai Lu, Jeffrey D. Rothstein, Merit E. Cudkowicz, Alex Zhavoronkov

Summary: In this study, an AI-driven target discovery platform called PandaOmics was used to analyze the expression profiles of CNS samples and direct iPSC-derived motor neurons from public datasets and Answer ALS. The study identified 17 high-confidence and 11 novel therapeutic targets, and verified their therapeutic effects in a fruit fly model. The research provides new insights into ALS pathophysiology and demonstrates the ability of AI to speed up the target discovery process.

FRONTIERS IN AGING NEUROSCIENCE (2022)

Review Clinical Neurology

ALSUntangled #67: rituximab

Xiaoyan Li, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T. Carter, Jesse Crayle, Merit Cudkowicz, Mazen Dimachkie, Eva L. Feldman, Jonathan Glass, Jill Goslinga, Terry Heiman-Patterson, Sartaj Jhooty, Rachel Lichtenstein, Isaac Lund, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Kristiana Salmon, Paul Wicks, Richard Bedlack

Summary: ALSUntangled reviews alternative and off-label treatments for ALS and finds that rituximab, a drug depleting B lymphocytes, lacks evidence of efficacy in ALS. One patient's experience with rituximab showed no benefit. Due to the known risks, we advise against using rituximab as an ALS treatment.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Meeting Abstract Clinical Neurology

TOPIRAMATE AS A DISEASE MODIFYING THERAPY FOR CRYPTOGENIC SENSORY PERIPHERAL NEUROPATHY (CSPN): A NEURONEXT IRIAL

Gordon Smith, J. R. Singleton, Marianne Chase, Christopher Coffey, Robin Conwit, Merit Cudkowicz, Dixie Ecklund, Janel Fedler, Anna Godjonsdottir, Tom Greene, Peter Hauer, Elizabeth Klingner, Cathy Revere

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2022)

No Data Available